A search of ClinicalTrials.govÂ shows there are 221 active, interventional CML trials with 125 recruiting. These trials are widely variable, with study topics covering novel drugs, treatment optimization of current treatment modalities, potential drug treatment combination regimens, the efficacy of treatment discontinuation, and immunotherapy.

Ongoing trials of note include the randomized international phase 3 study Evaluating Nilotinib Efficacy and Safety in Clinical Trials-Newly Diagnosed Patients (ENESTnd)

Other pertinent studies include trials that supported the first-line treatment with imatinib and dosing include the CML Study IV,

Pertinent studies and ongoing trials assessing tyrosine kinase inhibitor therapy discontinuation efficacy and candidate recommendations include the imatinib discontinuation study (STIM1),